The startup develops small molecule therapeutics that promote remyelination to repair damaged myelin sheaths in patients with multiple sclerosis. Their therapies aim to reverse the debilitating effects of the disease, enhancing neurological function and quality of life for affected individuals.
Funding
$13.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological diseases like multiple sclerosis, Alzheimer’s disease, and ALS damage myelin sheaths, disrupting nerve function and leading to physical and cognitive disability. Current treatments for these diseases often focus on managing symptoms or the immune response, but do not effectively repair the damaged myelin. There is an unmet need for therapeutics that can promote remyelination and limit disability progression.
Solution
Pheno Therapeutics is developing small molecule therapeutics that act as GPR17 antagonists to promote remyelination in neurodegenerative and demyelinating disorders. By blocking the GPR17 receptor, which is upregulated in diseased brains, the therapeutics unlock the brain’s endogenous repair systems. This approach aims to therapeutically target oligodendrocytes, a cell type in the brain responsible for action potential conduction, trophic and metabolic support, and axonal protection. Pheno Therapeutics' lead candidate, PTD802, is a novel oral remyelination agent designed to address the critical demyelination aspect of diseases like multiple sclerosis.
Target Audience
The primary target audience includes patients suffering from multiple sclerosis and other neurodegenerative diseases, as well as neurologists and healthcare providers seeking disease-modifying treatments.
Features
- Selective GPR17 antagonism to enhance oligodendrocyte function
- Small molecule therapeutics designed for oral administration
- Focus on promoting remyelination to repair damaged myelin sheaths
- Potential application in multiple sclerosis, Alzheimer’s disease, ALS, and other neurological disorders
- PTD802: a first-in-class oral remyelination agent